PRECIGEN, INC.
About PRECIGEN, INC.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $9.7M
- Net income
- -$250.6M
- Total assets
- $155.5M
- Market cap
- $1.3B
- Operating margin
- -1141.1%
- Net margin
- -2588.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $9.7M
- Operating expenses
- $120.2M
- Operating income
- -$110.5M
- Income tax
- $3.0K
- Net income
- -$250.6M
- EPS (basic)
- $-1.37
- EPS (diluted)
- $-1.37
Balance sheet
- Total assets
- $155.5M
- Current assets
- $115.2M
- Total liabilities
- $134.6M
- Current liabilities
- $37.3M
- Shareholders’ equity
- $20.9M
Cash flow
- Operating cash flow
- -$87.8M
- Investing cash flow
- -$1.5M
- Financing cash flow
- $90.0M
- Net cash flow
- $717.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.3B
- EPS (diluted)
- $-1.37
- Shares outstanding
- 357.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 8, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $250.6M in FY2025.
- Revenue declined 91% from FY2021 to FY2025.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PRECIGEN, INC..
Write a review
News about PRECIGEN, INC.
News & sentiment via Polygon.io
